Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Sep
24
Today In Oncology
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
Robert Kyle Myeloma Expert Dies at 98
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo